Alkermes

Alkermes

Yahoo Finance • 18 days ago

Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult A... Full story

Yahoo Finance • 19 days ago

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-deficit hyperactivity disorder (ADHD).... Full story

Yahoo Finance • 20 days ago

Alkermes rises on phase 1 results for ADHD drug ALKS 7290

[ADHD, attention deficit hyperactivity disorder, mental health, colorful hands of child, brain with cognitive difficulty] BeritK/iStock via Getty Images * Alkermes (ALKS [https://seekingalpha.com/symbol/ALKS]) is up ~7% in premarket tra... Full story

Yahoo Finance • 25 days ago

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN, September 16, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharma... Full story

Yahoo Finance • last month

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction va... Full story

Yahoo Finance • 2 months ago

Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?

It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit... Full story

Yahoo Finance • 2 months ago

Is Alkermes (ALKS) Priced For Orexin Success Or Too Rich?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes stock has delivered a strong 84.5% return over the past y... Full story

Yahoo Finance • 3 months ago

How Do the Vanguard S&P 500 Growth ETF and the State Street Small Cap Growth ETF Compare?

The choice between Vanguard S&P 500 Growth ETF (NYSEMKT:VOOG) and State Street SPDR S&P 600 Small Cap Growth ETF (NYSEMKT:SLYG) hinges on whether an investor prefers large-cap stability and tech dominance or the potential higher volatility... Full story

Yahoo Finance • 3 months ago

ALKS Crosses Above Average Analyst Target

In recent trading, shares of Alkermes plc (Symbol: ALKS) have crossed above the average analyst 12-month target price of $52.83, changing hands for $52.97/share. When a stock reaches the target an analyst has set, the analyst logically ha... Full story

Yahoo Finance • 3 months ago

American Express, Biogen upgraded: Wall Street's top analyst calls

American Express, Biogen upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by... Full story

Yahoo Finance • 3 months ago

Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says

Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Here Are Monday’s Best Wall Street Analyst Research Calls: Adobe, Applovin, Casey’s General Stores, CrowdStrike, Honeywell Aerospace, Salesforce, Synaptics, Terawulf, and More

Quick Read Futures climb on U.S.-Iran ceasefire reports as gold surges to $4,088 while Bitcoin tumbles to 20-month lows, extending weekly losses to nearly 17%. Adobe (ADBE) and Salesforce (CRM) both face steep downgrades at Phillip Securi... Full story

Yahoo Finance • 4 months ago

Alkermes plummets on mid-stage alixorexton data for narcolepsy

[Tired exhausted young businesswoman falling asleep at work desk] fizkes * Alkermes is down ~31% in after-hours trading Wednesday after reporting phase 2 study results of alixorexton for narcolepsy type 2. * The Vibrance-2 trial met i... Full story

Yahoo Finance • 4 months ago

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech

Key Points Invesco Pharmaceuticals ETF has a significantly lower five-year maximum drawdown and lower volatility profile than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF offers a more diversified approach with 151... Full story

Yahoo Finance • 4 months ago

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DUBLIN, June 03, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m.... Full story

Yahoo Finance • 5 months ago

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

– Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation High... Full story

Yahoo Finance • 5 months ago

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Stre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Preparation is key to understanding global trade compliance for trials

For global studies, investigational material and active pharmaceutical ingredients (API) are often shipped to sites in different countries from a central manufacturing base. This means that tax or VAT must be paid on the product upon entr... Full story

Yahoo Finance • 6 months ago

Alkermes Starts Phase 3 Orexin Trials As Narcolepsy Story Builds

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes (NasdaqGS:ALKS) has started Phase 3 Brilliance Studies fo... Full story

Yahoo Finance • 6 months ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story